At the recent AAPS National Biotech Conference 2025, pharmaphorum editor-in-chief Jonah Comstock caught up with Dr Dhaval Shah, a professor of pharmaceutical sciences at the University of Buffalo and ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...

To add to the relevance of this point, not only are HCPs expecting them, but we know that they work. In fact, as IQVIA’s ChannelDynamics shows, the impact of remote detailing on HCPs reported ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

The industry is showing its teeth, as companies have started slashing positions. Ben Hargreaves reviews how the job losses that started earlier in the biotech industry have quickly spread to all ...

Advances in multi-omics, artificial intelligence (AI), deep learning (DL), ageing biomarkers, precision imaging, ageing clocks, robotics, and smart technologies have enabled researchers to ...